ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

http://oncologypro.esmo.org/Meeting-Resourc...on-ablation-device-Animal-experimental-study

Irreversible electroporation (IRE) is a promising novel technique for the ablation of tumors. An advantage of IRE is its mechanism to remove undesired cells by affecting the cell membrane without...

Date: 28 Jun 2017
Presenter: Geeho Min
Resources: Abstract
Topics: Gastrointestinal Cancers, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...atients-with-metastatic-WHO-grade-3-GEP-NECs

We investigated the impact of pathologic differentiation (well or poorly differentiated) in metastatic grade 3 GEP-NEC patients receiving etoposide and platinum (EP)-based therapy, and evaluated a more...

Date: 28 Jun 2017
Presenter: Song Ee Park
Resources: Abstract
Topics: Gastrointestinal Cancers, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...bitors-A-systematic-review-and-meta-analysis

We conducted a systematic review and meta-analysis to assess the risk of gastrointestinal (GI) and hepatic adverse events (AEs) related to using the enzyme poly ADP ribose polymerase (PARP) inhibitors in patients with solid tumors.

Date: 28 Jun 2017
Presenter: Hoda Ahmed
Resources: Abstract
Topics: Gastrointestinal Cancers, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...ermethylation-in-gastric-cancer-pathogenesis

Gastric cancer develops through multistep process, and the molecular basis of gastric cancer carcinogenesis and progression is largely unknown. As a family of zinc metalloenzymes, the carbonic anhydrases ...

Date: 28 Jun 2017
Presenter: Xianglan Zhang
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

http://oncologypro.esmo.org/Meeting-Resourc...nknown-primary-A-single-UK-centre-experience

In the United Kingdom between 2006-10, 57% of patients with Malignancy of Unknown Origin (MUO) and Carcinoma of Unknown Primary (CUP) presented via the emergency route with a dismal survival rate of 10% at 6 months.

Date: 28 Jun 2017
Presenter: Laura Jaques
Resources: Abstract
Topic: Carcinoma of Unknown Primary Site

http://oncologypro.esmo.org/Meeting-Resourc...it-promise-an-early-return-of-bowel-function

The hyperthermic intraperitoneal chemotherapy (HIPEC) has been widely accepted as a useful palliative treatment for peritoneal carcinomatosis due to advanced malignances.

Date: 28 Jun 2017
Presenter: Jinning Ye
Resources: Abstract
Topics: Gastrointestinal Cancers, Palliative and Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...erience-of-a-single-Portuguese-cancer-centre

Streptozocin based chemotherapy is historically the most used association to treat metastatic neuroendocrine tumors. However, in recent years temozolomide associated with capecitabine has emerged as...

Date: 28 Jun 2017
Presenter: João Ribeiro
Resources: Abstract
Topic: Neuroendocrine Cancers

http://oncologypro.esmo.org/Meeting-Resourc...lation-with-clinical-pathological-parameters

The aim of this study was to determine whether overexpression of c-MET or HER2 had an effect on the clinical-pathological parameters and/or the prognosis of gastric carcinoma, as well as a direct correlation among those parameters.

Date: 28 Jun 2017
Presenter: Patrick Stuebs
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

http://oncologypro.esmo.org/Meeting-Resourc...Bone-metastasis-from-gastrointestinal-cancer

Bone metastasis from gastrointestinal cancer are rare. We evaluate the prevalence of this situation and its management.

Date: 28 Jun 2017
Presenter: Rachid Tanz
Resources: Abstract
Topic: Gastrointestinal Cancers

http://oncologypro.esmo.org/Meeting-Resourc...pathology-department-of-FSI-Hospital-Tunisia

The homeobox transcription factor CDX2 is an immunohistochemical maker whose expression in the adult is normally restricted to the intestinal epithelium . It’s implicated in the development and maintenance of the intestinal mucosa.

Date: 28 Jun 2017
Presenter: Khdija Bellil
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer